Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 14/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 10/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.35 |
| ▸ | CNR2 | P34972 | 4/20 | 0.35 |
| ▸ | CNR1 | P21554 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | G6PD | P11413 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL717800 | 0.86 | TAS1R3 (0.37) | CNR2CNR1NPC1ALDH1A1CYP1A2 | |
| SCHEMBL718050 | 0.85 | PTGS2 (0.36) | HRH1CYP2D6CHRM1KCNH2CNR2 | |
| SCHEMBL717816 | 0.83 | CNR2 (0.34) | CNR2CNR1NPC1ALDH1A1CYP1A2 | |
| SCHEMBL718342 | 0.81 | HRH1 (0.35) | HRH1CYP2D6CHRM1KCNH2CYP3A4 | |
| SCHEMBL716543 | 0.77 | HRH1 (0.35) | HRH1CYP2D6CHRM1KCNH2CNR2 | |
| SCHEMBL14156519 | 0.72 | CNR2 (0.43) | HRH1CYP2D6CHRM1KCNH2CNR2 | |
| SCHEMBL916315 | 0.72 | TSHR (0.49) | CYP2D6G6PDKMT2A | |
| SCHEMBL1407856 | 0.71 | TRPA1 (0.42) | CYP1A2KMT2A | |
| SCHEMBL714982 | 0.71 | HRH1 (0.42) | HRH1CYP2D6CHRM1KCNH2CNR2 | |
| SCHEMBL916701 | 0.71 | KDM4E (0.36) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9090639-B2 | Cold menthol receptor-1 antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2015-07-28 | — | — | US | disclosed |
| US-20140100194-A1 | COLD MENTHOL RECEPTOR-1 ANTAGONISTS | JANSSEN PHARMACEUTICA, NV (BE) | 2014-04-10 | — | — | US | disclosed |
| US-8629281-B2 | Cold menthol receptor-1 antagonists | JANSSEN PHARMACEUTICA, NV (BE) | 2014-01-14 | — | — | US | disclosed |
| US-8558011-B2 | Cold menthol receptor-1 antagonists | JANSSEN PHARMACEUTICA, NV (BE) | 2013-10-15 | — | — | US | disclosed |
| EP-2029614-B1 | COLD MENTHOL RECEPTOR-1 ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2013-01-23 | — | — | EP | disclosed |
| US-20120184510-A1 | COLD MENTHOL RECEPTOR-1 ANTAGONISTS | COLBURN RAYMOND W (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120053347-A1 | COLD MENTHOL RECEPTOR-1 ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-03-01 | — | — | US | disclosed |
| US-7897781-B2 | Cold menthol receptor-1 antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-01 | — | — | US | disclosed |
| EP-2029614-A2 | COLD MENTHOL RECEPTOR-1 ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2009-03-04 | — | — | EP | disclosed |
| US-20080287398-A1 | COLD MENTHOL RECEPTOR-1 ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-11-20 | — | — | US | disclosed |
| US-20080027029-A1 | COLD MENTHOL RECEPTOR-1 ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-31 | — | — | US | disclosed |
| WO-2007134107-A2 | COLD MENTHOL RECEPTOR-1 ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027029-A1 | COLD MENTHOL RECEPTOR-1 ANTAGONISTS | TRPM8, TRPM5, TRPM7 | HRH1 100/4885CYP2D6 1625/4885CHRM1 235/4885 |
| US-20120184510-A1 | COLD MENTHOL RECEPTOR-1 ANTAGONISTS | TRPM8, TRPM5, TRPM7 | HRH1 100/4885CYP2D6 1625/4885CHRM1 235/4885 |
| US-20120053347-A1 | COLD MENTHOL RECEPTOR-1 ANTAGONISTS | TRPM8, TRPM5, TRPM7 | HRH1 100/4885CYP2D6 1625/4885CHRM1 235/4885 |
| US-20080287398-A1 | COLD MENTHOL RECEPTOR-1 ANTAGONISTS | TRPM8, TRPM5, TRPM7 | HRH1 100/4885CYP2D6 1625/4885CHRM1 235/4885 |
| US-20140100194-A1 | COLD MENTHOL RECEPTOR-1 ANTAGONISTS | TRPM8, TRPM5, TRPM7 | HRH1 100/4885CYP2D6 1625/4885CHRM1 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.